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ScienceDirectTowards a more precise therapy in cancer: Exploring
epigenetic complexity
Fernando P. Cossío1,2, Manel Esteller3,4,5,6 and
María Berdasco7,8Abstract
A plethora of preclinical evidences suggests that pharmaco-
logical targeting of epigenetic dysregulation is a potent strategy
to combat human diseases. Nevertheless, the implementation
of epidrugs in clinical practice is very scarce and mainly limited
to haematological malignancies. In this review, we discuss
cutting-edge strategies to foster the chemical design, the bio-
logical rationale and the clinical trial development of epidrugs.
Specifically, we focus on the development of dual hybrids to
exploit multitargeting of key epigenetic molecules deregulated
in cancer; the study of epigenetic-synthetic lethality in-
teractions as a mechanism to address loss-of-function muta-
tions, and the combination of epidrugs with other therapies
such as immunotherapy to avoid acquired chemoresistance
and increase therapy sensitivity. By exploring these chal-
lenges, among others, the field of epigenetic chemical biology
will increase its potential for clinical benefit, and more effective
strategies targeting the aberrant epigenome in cancer are
likely to be developed both in haematological and solid
tumours.
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For the last two decades, epigenetic dysregulation has
been recognized as a key factor contributing to human
disorders. This is boosting an increasing number of
studies into the field of epigenetic drug discovery [1,2].
Epidrugs, defined as small-molecule inhibitors that
target either the epigenome or enzymes with epigenetic
activity, have been developed for the three categories of
epigenetic regulators (writers, readers and erasers).
Although writers are responsible for adding chemical
groups to histones or DNA (e.g., histone acetyl-
transferases (HATs), histone methyltransferases
(HMTs) or DNA methyltransferases (DNMTs); erasers
remove them (e.g., histone deacetylases (HDACs) or
histone demethylases (HDMTs). In addition, epige-
netic modifications are recognized by a set of reader
domains that are recruited to specific epigenetic marks
and act as effector proteins (e.g., methyl-binding do-
mains proteins or bromo- and extra-terminal (BETs)
domain proteins). At present, the FDA-approved
epidrugs include therapies with the following HDAC
inhibitors: Vorinostat and Romidepsin for refractory
cutaneous T cell lymphoma, belinostat for peripheral T
cell lymphoma or panobinostat for multiple myeloma.
Approvals also included the DNMT inhibitor Decita-
bine which is administrated in patients with haemato-
logical malignancies, such as myelodysplastic
syndromes, acute myeloid leukaemia, and chronic
myelomonocytic leukaemia. After the first- and second-
generations of epidrugs, possibilities for epidrugCurrent Opinion in Chemical Biology 2020, 57:41–49
42 Chemical genetics and epigeneticsdevelopment are now being explored in erasers, and
BETand methyl-binding domains proteins inhibitors are
undergoing clinical evaluation for efficacy in different
cancer settings [2].
Despite their promise, there many challenges to be
resolved for efficient use of epidrugs in the treatment of
human cancer, including the lack of specificity of
epidrugs, disappointing success in solid tumours and the
acquisition of drug chemoresistance leading to higher
risk of tumour relapse. Herein, we review the cutting-
edge approaches in the field of chemical biology and
molecular biology that are currently being taken to
improve the translation of epidrug therapy into clinical
practice. Although still in its infancy, the interesting
concept of epidrug multitargeting, the potential of the
epigenetic-based synthetic lethality strategies and the
use of epidrugs in combination with other therapies
(such as immunotherapy) are introduced as alternativesFigure 1
Dual inhibitors involving epigenetic and nonepigenetic targets (2017–2019). D
acetyltransferase; HDAC1, histone deacetylase 1; IDO1, indoleamine 2,3-diox
programmed cell death protein 1; VEGFR, vascular endothelial growth factor
Current Opinion in Chemical Biology 2020, 57:41–49for optimizing the clinical translation of epigenetic
therapy.From the magic bullet paradigm to
multitarget epigenetic inhibitors
Multitarget therapeutic strategies can involve separate
molecules that give rise to well-known combined thera-
pies. An alternative strategy consists of incorporating two
biologically active units directed to their respective
therapeutic targets. These moieties are connected by a
spacer component bound to both units by covalent bonds.
This strategy has yielded dual inhibitors, designed as
‘inhibitor(1)dspacerdinhibitor(2)’ compounds, which
in turn act against epigenetic and nonepigenetic enzymes
[3]. In the last three years, several additional examples
have been reported (Figures 1 and 2).
As far as the design, chemical synthesis and biological
validation of novel epigenetic/nonepigenetic dualBD, DNA-binding domain; DNMT1, DNA methyltransferase 1; HAT, histone




Dual inhibitors involving solely epigenetic targets (2017–2019). DNMT1, DNA methyltransferase 1; EZH1, enhancer zeste homologue 1; EZH2, enhancer
zeste homologue 2; HDAC1, histone deacetylase 1; LSD1, lysine specific demethylase 1; G9a (EHMT2), histone– lysine N-methyltransferase 2.
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esting novel approach consists of incorporating into the
same chemical entity several bioactive components not
connected by covalent bonds. Thus, Ruan et al. [4]
synthesized a reactive oxygen species (ROS)eresponsive
polymer by condensation of polyvinyl alcohol with a
boronic diacid that creates a N1-(4-boronobenzyl)-N3-
(4-boronophenyl)-N1,N1,N3,N3-tetramethylpropane-
1,3-diaminium (TSPBA) cross-linker, which can be
decomposed in vivo in the presence of ROS. This
hydrogel was combined with pH-sensitive
CaCO3 nanoparticles (NPs) to generate a combined
ROS/Hþ biosensitive depot that can encapsulate bioac-
tive species to be released into tumour microenviron-
ments. These latter molecules were Zebularine [5], a
known demethylating reagent, and an antibody against
programmed death-1 (PD1) receptor [6], which is
expressed in immune cells, including CD8þTcells. The
combined Zebularine-polyvinyl alcohol-TSBPA-aPD1-
CaCO3-NP chemical entity 1 demonstrated its efficacy
in the inhibition of tumour growth and in prolonging the
survival time of B16F10 melanoma bearing tissues [6].
This approach establishes a link between combined and
dual therapies in cancer, as well as between epigenetic
and immunotherapies (later discussed in this review).www.sciencedirect.comOther recent developments in dual epigenetic/nonepi-
genetic inhibitors are gathered in Figure 1. Inhibitor 2 is
quite different to other dual covalent bioactive mole-
cules because it combines a DNA-binding
domain consisting of a poly(1H-pyrrole) oligomer and a
HAT inhibitor [7]. This dual molecule results in a
sequence-specific inhibitor that shows promising inhib-
itory properties and antiproliferative effects in the
upregulation of p53 genes thus initiating p53-dependent
apoptosis. Many recently reported molecules include
HDACs as epigenetic targets. Both hydroxamic acids and
amides derived from ortho-phenylenediamines, well-
known chelating groups for Zn(II)-dependent HDACs
[2], have been reported. Dual inhibitor 3 includes two
groups that simultaneously inhibit nicotinamide
phosphoribosyltransferase and HDAC1, thus combining
highly relevant metabolic and epigenetic targets [8].
The former inhibitory moiety consists of a substituted
thiourea and the latter includes the orthophenylene-
amine Zn(II)-chelating group. Both units are covalently
connected by a very short para-phenylene unit. This
molecule showed excellent activity and efficiently
induced cell apoptosis and autophagy. In addition, it
showed promising in vivo antitumour activity in the
HCT116 xenograft model [8]. In the same vein,Current Opinion in Chemical Biology 2020, 57:41–49
44 Chemical genetics and epigeneticscompound 4 shows a design based on the hydroxamic
group as the chelating group of HDAC1. This dual in-
hibitor appears to be more potent than 3, and also
showed promising results with the HCT116 xenograft
model [9]. Compound 5 also contains the amide
HDAC1-inhibitory group, whereas the second bioactive
moiety consists of an heterocyclic oxime that binds
indoleamine 2,3-dioxygenase 1 [10]. This latter haem-
containing dioxygenase catalyses the transformation of
L-Trp into N-formylkynurenines, which results in tryp-
tophan depletion and subsequent inhibition of the pro-
liferation of T lymphocytes [10]. Therefore, dual
inhibitor 5 also connects epigenetic and immunothera-
peutic targets. This compound inhibited both enzymes
in the nanomolar range (Figure 1) and showed excellent
in vivo antitumour activity in the murine LLC tumour
model [10]. Finally, compounds 6 and 7 demonstrated
their inhibitory potency of class I HDACs and vascular
endothelial growth factor (VEGFR) [11]. Inhibition of
the first epigenetic target was accomplished in 6 by a
moiety analogous to the known HDAC inhibitor MS-275
[12], whereas the second target is incorporated in 6 and 7
by means of a combined 2-methyl-2H-imidazole/pyrim-
idine polyheterocycle similar to that which is present in
approved VEGFR inhibitor Pazopanib [13]. Both com-
pounds exhibited HDACi and VEGFRi activities com-
parable with those found for MS-275 and pazopanib,
aside additional activities not present in the separate
units. In addition, compound 5 showed good pharmaco-
kinetic profiles and oral bioavailability (72%), as well as a
promising antitumour efficacy in the HT-29 xenograft
model.
Among dual epigenetic inhibitors, recent examples
include a dual inhibitor of the HMTs enhancer zeste
homologues 2 and 1 (EHZ2 and EHZ1) triggering
trimethylation of the Lys-27 residue of histone 3
(H3K27). Overexpression of EZH2 and subsequent
hypermethylation of H3K27 is present in the progres-
sion of PRC2-dependent tumours. Bioavailable com-
pound 8 (also known as UNC1999) [14] inhibits both
EZH2 and EZH1 (Figure 2). Most interestingly, it
induced antimyeloma in vitro activity in combination
with proteasome inhibitor Bortezomib [15]. A poten-
tially interesting combination of epigenetic targets as-
sociates methylation processes in histones and DNA. In
particular, the inhibition of HMT G9a (also known as
EHMT2) methylates H3K9, which is overexpressed in
many tumours, decreases cancer cell proliferation and
hampers the development of metastasis [16,17]. 4-
Aminoquinoline 9 (CM-272) is a promising dual G9a/
DNMT1 inhibitor, with potencies in the nanomolar
range for both targets [16,17]. In addition, significantly
prolonged survival of acute myeloid leukaemia, Acute
lymphoblastic leukemia (ALL) and Diffuse large B-cell
lymphoma (DLBCL) xenogenic models was described.Current Opinion in Chemical Biology 2020, 57:41–49Other structural analogues [18] of 9 showed also
promising dual G9a/DNMT1 inhibitory activity. Other
dual inhibitors shown in Figure 2 involve HDACs as one
of the classes of epigenetic targets. Compounds 10 [19],
11 [20] and 12 [21] incorporate hydroxamic acid units as
HDAC-chelating groups, whereas 13 [22] possesses the
alternative ortho-phenylenediamine unit as the
preferred chelating group to HDAC1.Compound 10 also
inhibits lysine specific demethylase 1 (LSD1), an
enzyme that is present in the CoREST corepressor
complex and demethylates mono- and di-methylated
H3K4. The trans-aminocyclopropyl moiety of 10 is
responsible for the inhibition of LSD1, with a potency
within the low micromolecular range [19]. Compound
11 combines HDAC1,6 nM inhibition with micromolar
binding to DNMT1 [20]. In contrast, compound 12
inhibits both HDACs and G9a, thus combining deace-
tylases and methyl transferases as dual targets [21].
Finally, compound 13 (Corin) inhibits HDAC1 and
LSD1, thus targeting the CoREST complex by encom-
passing the chief features of Entinostat and Tranylcy-
promine [22], and showed very promising therapeutic
potential in slowing tumour growth in a murine mela-
noma xenograft.Targeting loss-of-function by synthetic
lethality epigenetic approaches
Several examples of epigenetic therapy take advantage
of the mutations found in all major classes of epigenetic
proteins and have been explored as targets for therapy
[23]. From a mechanistic consideration, mutations can
be divided into two categories: loss- or gain-of function
of the epigenetic enzyme. Although it is possible to
inhibit gain-of-function of epigenetic enzymes (as
example overexpression of the HMTs EZH2 or MLL),
loss-of-function mutations are more difficult to target.
An innovative approach based on the concept of syn-
thetic lethality has been implemented in recent years
opening up new strategies in drug development.
Synthetic lethality refers to a genetic interaction be-
tween two genes in which the loss of one of them has
little effect on cellular viability, whereas loss of both
genes leads to cellular lethality. This interaction pro-
vides a therapeutic opportunity by inhibiting the second
partner (e.g., pharmacological inhibition) in those tu-
mours with genetic mutations affecting the other part-
ner. A normal cell without genetic mutations would
tolerate the pharmacological inhibition, while it would
be lethal for the tumour cell without the two functional
genes (Figure 3a). After the first FDA-approved syn-
thetic lethal drug therapy pairing BRCA1/2 mutations
with PARP inhibitor olaparib treatment in ovarian cancer
[24], studies of synthetic lethal pairs involving
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Epigenetic synthetic lethality. (a) Synthetic lethality refers to a genetic interaction between two genes (e.g., gene A and gene B) in which the loss of gene
A or gene B has little effect on cellular viability, whereas loss of both genes leads to cellular lethality. (b) Epigenetic-related synthetic approaches as
therapeutic opportunity in tumours with specific mutations. The pharmacological inhibition of one partner of the pair (e.g., pharmacological inhibition of
gene B in tumours harbouring gene A mutations) could result in cellular lethality. A normal cell without genetic mutations would tolerate the pharma-
cological inhibition of gene B. CRF, chromatin remodelling factor; HAT, histone acetyltransferase; HMT, histone methyltransferase.
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epigenetic mutations and epigenetic inhibitors, epige-
netic mutations and nonepigenetic inhibitors and
oncogene mutations and epigenetic inhibitors [25]
(Figure 3b).
One pioneer example of epigenetic-related synthetic
lethality entering in clinical trials was the use of in-
hibitors of the HMT DOT1L, such as pinometostat, in
the treatment of MLL-fusion leukaemia [26]. The
MLL-fusion results in DOT1L recruitment and
epigenetic-mediated activation of well-known drivers of
tumorigenesis (e.g., HOXA9, MEIS1) together with
proteins involved in protection of MLL fusion proteins
from autophagic degradation (e.g., LAMP5) [27]. The
pinometostat inhibition effect on DOT1L selectively
killed MLL-fusion leukaemia cells but not normal cells
without the MLL genetic aberrations throughout
downregulating LAMP5 and enhancing the selective
autophagic degradation of MLL oncoproteins [27].www.sciencedirect.comAdditional examples of synthetic lethality between
epigenetic alterations and epigenetic inhibitors exist,
specifically involving mutations in chromatin remodel-
ling proteins. Members of the SWI/SNF complex are
frequently mutated in cancer, includingmutations in the
tumour suppressors ARID1A or SMARCB1 [23]. PRC2 is
another crucial chromatin complex that includes the
HMT EZH2, and its deregulation is associated with
multiple cancers [28]. To note that there is an epigenetic
antagonism between SWI/SNF and PRC2 complexes,
which has been the focus of synthetic legal strategies. In
this way, pharmacological inhibition of EZH2 is a syn-
thetic lethal strategy in tumours harbouring SWI/SNF
mutations [28,29]. Treatment with GSK126, a specific
inhibitor of EZH2, decrease tumorigenesis is preclinical
models of ovarian tumours with ARID1Amutations [29].
Recently, an elegant work performed by Meyer et al.
[30] described relevant applications of synthetic
lethality approaches involving HAT activities in lym-
phomas. Inactivating mutations of the CREBBP andCurrent Opinion in Chemical Biology 2020, 57:41–49
46 Chemical genetics and epigeneticsEP300HATs aremutually exclusive genetic alterations in
diffuse large B cell lymphoma and follicular lymphoma.
However, treatments with small molecule inhibitors that
are selective for CREBBP and EP300 (i.e., the bromo-
domain inhibitor CCS1477 and the preclinical HAT
domain inhibitor CU329) abolished the EP300-
dependency in CREBBP mutants and resulted in
diminished tumour proliferation in murine models [30].
Nonepigenetic inhibitors have been also explored in
synthetic lethality therapies involving tumours with
epigenetic alterations. PARP inhibitors have synthetic
lethal effects with epigenetic enzymes in cancer. The
HMT KMT2C (also known as MLL3) gene has a high
frequency in bladder cancer. The reduction of KMT2C
activity results in decreased H3K27ac-dependent
expression of genes from the DNA repair pathways
(particularly in the homologous recombination pathway)
associated with higher endogenous DNA damage and
genomic instability in the tumour cells, and conse-
quentially increased sensitivity to the PARP inhibitor
Olaparib in epithelial carcinomas [31]. Similarly, a mo-
lecular interaction between the HMT SETD2, which
catalyses the methylation at H3K36 enriched at pro-
moters with active transcription, and PI3Kb kinase has
been explored in preclinical models of renal cell carci-
noma [32]. Treatment with inhibitors of PI3Kb/AKT
pathway causes synthetic lethality with SET2D loss-of-
function and increased tumour inhibition in renal cancer
cells [32].
Finally, a synthetic lethal interaction between an onco-
gene mutation (nonepigenetic) and the epigenetic drug
has been described for the transcription factor GATA3
and the HMTs G9A and GLP (also known as EHMT2
and EHMT1, respectively) in breast cancer [33].
Interestingly, not only loss-of-function but also gain-of-
function of oncogenes could be exploited in epigenetic-
related synthetic lethality approaches. Treatment with
EZH2 inhibitors results in decreased metastaticTable 1
Examples of current clinical trials involving epidrugs in combination
colorectal cancer; DNMTi, DNA methyltransferase inhibitor; HDACi, h
itor; HNSCC, head and neck squamous cell carcinoma; HMTi, histone






NCT01928576 II Azacytidine (DNMTi), entinostat
(HDACi)
Nivolumab
NCT02638090 I/II Vorinostat (HDACi) Pembrolizu
NCT02635061 I ACY 241 (HDACi) Nivolumab
NCT03179930 II Entinostat (HDACi) Pembrolizu
NCT02619253 I Vorinostat (HDACi) Pembrolizu
NCT02453620 I Entinostat (HDACi) Ipilimumab
nivoluma
Current Opinion in Chemical Biology 2020, 57:41–49potential in TP53-overexpressing prostate tumours and
represents new therapeutic opportunities for treatment
of advanced solid cancers [34].Epigenetic therapy in combination with
other drugs to boost immune response or
drug sensitivity
In the recent years, results from preclinical and phase I/
II clinical trials support that, beyond their potential as
monotherapies, epigenetic drugs could have important
roles in combination with other anticancer therapies.
Epidrugs, especially HDACi and DNMTi, have been
tested in combination with: chemotherapy (e.g., vori-
nostat plus capecitabine and Cisplatin in unresectable
gastric cancer [35]), radiotherapy (e.g., vorinostat plus
pelvic radiotherapy in gastric cancer [36]), hormonal
therapy (e.g., panobinostat plus bicalutamide in
castration-resistant prostate cancer [37]) or targeted
therapies (e.g., Abexinostat plus the tyrosine kinase
inhibitor pazopanib in advanced renal cell carcinoma
[38]). A synergistic effect to favour sensitization of the
cancer cell to the giving therapy and for overcoming
acquired chemoresistance has been observed.
Among the combinatorial possibilities, enhancing the
anticancer efficacy of immunotherapy through combi-
nation with epigenetic drugs is receiving the most
attention [39]. Positive results for the immunogenicity of
tumour cells are described when epidrugs are adminis-
trated together with immune checkpoint blockade
therapy (anti-PD1/PDL1 therapy in combination with
HDACi in nonesmall-cell lung cancer [40]) and adoptive
cellular immunotherapy (e.g., HDACi plus CD19-CAR
CTL therapy in non-Hodgkin’s lymphoma [41]). A
summary of the most recent examples of clinical trials is
provided in Table 1. Although the mechanisms of action
by which the epidrug therapies modulate the immune
response still need further investigation, the reactivation
of tumour-surface antigens, endogenous retroviruses and
proteins for the major complex of histocompatibilitywith immunotherapy agents. BETi, bromodomain inhibitor; CRC,
istone deacetylase inhibitor; HDMTi, histone demethylase inhib-
methyltransferase inhibitor; SGC, salivary gland cancer; NSCLC,
ladder cancer.
otherapy agent Cancer type Status
(anti-PD1) NSCLC Recruiting
mab (anti-PD1) NSCLC Recruiting
(anti-PD1) NSCLC Recruiting
mab (anti-PD1) Lymphoma Recruiting










Epigenetic drug Immunotherapy agent Cancer type Status
NCT03552380 II Entinostat (HDACi) Ipilimumab (anti-CTLA-4),
nivolumab (anti-PD1)
RCC Recruiting
NCT03250273 II Entinostat (HDACi) Nivolumab (anti-PD1) Cholangiocarcinoma,
pancreatic cancer
Recruiting
NCT03278782 II Romidepsin (HDACi) Pembrolizumab (anti-PD1) Lymphoma Recruiting
NCT03150329 I Vorinostat (HDACi) Pembrolizumab (anti-PD1) Lymphoma Recruiting
NCT03220477 I Guadecitabine (DNMTi) plus
mocetinostat (HDACi)
Pembrolizumab (anti-PD1) NSCLC Recruiting
NCT03903458 I Tinostamustine (HDACi) Nivolumab (anti-PD1) Cutaneous melanoma Recruiting
NCT02546986 II CC-486 (DNMTi) or placebo Pembrolizumab (anti-PD1) NSCLC Active, not recruiting
NCT02437136 I/II Entinostat (HDACi) Pembrolizumab (anti-PD1) NSCLC, cutaneous
melanoma and CRC
Active, not recruiting
NCT02538510 I/II Vorinostat (HDACi) Pembrolizumab (anti-PD1) HNSCC, SGC Active, not recruiting
NCT02032810 I Panobinostat (HDACi) Ipilimumab (anti-CTLA-4) Cutaneous melanoma Active, not recruiting
NCT02909452 I Entinostat (HDACi) Pembrolizumab (anti-PD1) Advanced solid tumours Active, not recruiting
NCT02395627 II Vorinostat (HDACi) plus
tamoxifen (anti-oestrogen)
Pembrolizumab (anti-PD1) Breast cancer Active, not recruiting
NCT02512172 I Romidepsin (HDACi),
azacytidine (DNMTi)
Pembrolizumab (anti-PD1) CRC Active, not recruiting
NCT02697630 II Entinostat (HDACi) Pembrolizumab (anti-PD1) Ocular melanoma Active, not recruiting




NCT02708680 II Entinostat (HDACi) Atezolizumab (anti-PDL1) Breast cancer Active, not recruiting
NCT02220842 I Tazemetostat Atezolizumab (anti-PDL1),
obinutuzumab
Lymphoma Active, not recruiting
NCT03525795 I/II CPI-1205 (HMTi) Ipilimumab (anti-CTLA-4) Advanced solid tumours Active, not recruiting
NCT02250326 II CC-486 (DNMTi) or paclitaxel
(targeted therapy)
Durvalumab (anti-PDL1) NSCLC Active, not recruiting





Advanced solid tumours Active, not recruiting
HDACi, histone deacetylase inhibitor; DNMTi, DNA methyltransferase inhibitor; NSCLC, non–small-cell lung cancer; CRC, colorectal cancer; PD1,
programmed cell death protein 1.
Epidrug development in advanced precision oncology Cossío et al. 47could be mediators of the increased tumour visibility to
the host immune system [42]. In spite of its preliminary
success, some frequent limitations of epidrugs also need
to be solved in combinational therapy, including the
reduction of the toxicity and the secondary effects. Im-
provements in the immunotherapy schemes will also
benefit from systems biology approaches. In this regard, a
recentmathematicalmodel to predict synergies between
BET inhibitors and anti-CTLA4 immunotherapy has
been proposed for the optimization of combinatory
therapy in breast cancer [43].Conclusions
A simplified vision of epigenetic regulation and the use
of inappropriate cohorts in clinical trials are undoubtedly
limiting factors to the success of epidrugs as therapeutic
agents. At present, we are envisioning an approach
which moves “from the simplest to the most complex”. We are
accepting that epigenetic modifications are not stand
alone processes because several epigenetic proteins
(and also not epigenetic) contribute to regulate chro-
matin accessibility, as do several nonepigenetic proteins.www.sciencedirect.comInhibition of a single epigenetic alteration can have
global and local effects on chromatin conformation
affecting multiple biological processes (e.g., not only
gene regulation but also DNA repair or DNA recombi-
nation could be affected after treatments) and multiple
biological pathways (e.g., the HAT CBP/EP300 acety-
lates lysine residues of histones H3 and H4, as well as
the oncogene p53 [44]). Furthermore, the effect of
targeting a specific mark could result in further changes
in different modifications (e.g., treatments with HDAC
inhibitors could increase acetylation of histones but also
affect histone methylation [45]). Therefore, research in
the field of systems biology applied to epigenetic com-
plexes would allow us to exploit the benefits of targeting
complexity, such as the aforementioned strategies for
development of dual inhibitors.
Undoubtedly, it is not only a question of chemical drug
design. Basic research to unravel the mechanisms of
action of tumour cell progression and response to ther-
apy (e.g., molecular pathways associated with tumoral
evasion from the host immune system), the broaderCurrent Opinion in Chemical Biology 2020, 57:41–49
48 Chemical genetics and epigeneticscharacterisation of the genetic and epigenetic mutations
acting as drivers in a tumour cell and a better stratifi-
cation of the patients entering clinical trials (i.e.,
development of predictive biomarkers of response)
would contribute to the development of more adequate
clinical trials involving epigenetic drugs. In summary,
the studies reviewed here suggest promising opportu-
nities for targeting epigenetic alterations to make
further advances in precision oncology.Author contributions
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